The obesity-like effects produced by the chronic intracerebroventricular ( i.c.v.) neuropeptide Y (NPY) infusion in normal rats require the presence of glucocorticoids, as none of them occurs when NPY is similarly infused in adrenalectomized rats. NPY effects are present again when i.c.v. NPY is infused together with i.c.v. dexamethasone in adrenalectomized animals. The inhibitory effect of leptin on food intake and body weight observed when the hormone is i.c.v. administered to normal rats is markedly enhanced and longer lasting when the same dose of leptin is i.c.v. administered to adrenalectomized rats. Glucocorticoid administration to adrenalectomized rats dose-dependently reduces, then abolishes, this potent effect of leptin. Thus, glucocorticoids limit leptin-induced effects. The chronic i.c.v. infusion of glucocorticoids (dexamethasone) to normal rats produces an obesity syndrome with its several abnormalities. This appears to be due to glucocorticoid-elicited increases in hypothalamic NPY levels together with decreases in those of CRH. Thus, the status of the hypothalamo ± pituitary ± adrenal axis and related glucocorticoid output is a relevant facet of body weight homeostasis. It may be a deleterious environmental factor responsible for the development of obesity, insulin as well as leptin resistance, and type 2 diabetes.
Introduction
Normal body weight homeostasis is ensured by functional relationships of, at least, hypothalamic neuropeptide Y (NPY), a stimulator of food intake, and of adipose tissue leptin, an inhibitor of food intake. 1, 2 Indeed, it has been shown that increased hypothalamic NPY levels stimulated insulin and glucocorticoid secretion by increasing the activity of the efferent parasympathetic branch of the autonomous nervous system, as well as that of the hypothalamo ± pituitary ± adrenal (HPA) axis, respectively. Such NPYelicited hyperinsulinemia and hypercorticism were demonstrated to alter nutrient partitioning, favoring adipose tissue lipogenic activity and lipid storage, while decreasing the effect of insulin on muscle glucose oxidation. The combined effect of NPYelicited hyperinsulinemia and hypercorticism resulted in increased secretion of leptin by white adipose tissue. 3 ± 8 Secreted leptin, once in the central nervous system and acting within the hypothalamus, decreased hypothalamic NPY levels. 9 ± 11 This resulted in decreased food intake and body weight 10 and in leptin-induced hormono-metabolic changes. 12 The latter were shown to result in decreased insulin output, decreased adipose tissue lipogenic activity and fat storage, increased glucose disposal, increased uncoupling protein expression and, presumably, increased energy dissipation as heat. Many central effects of leptin were attributed to its ability to increase the activity of the efferent branch of the sympathetic nervous system. 12 The respective hormono-metabolic effects of NPY and leptin are thus almost the mirror image of each other, and the dailȳ uctuations in their respective levels ensure a normal body homeostasis. 1, 2 In most obesity syndromes in animals, hypothalamic leptin receptors are mutated or dysfunctional, leptin's action is impaired, and hypothalamic NPY levels remain high, thereby producing and maintaining obesity. 1, 2 When considering obesity, syndromes, of special interest was the previous observation that this pathology in rodents could be normalized or prevented by adrenalectomy (cited in ref. 13) . Moreover, the administration of glucocorticoids to adrenalectomized obese rodents resulted in the reappearance of the obesity syndromes (cited in ref. 13) . Such effects of adrenalectomy and of glucocorticoid supplementation remained elusive mechanistically. It was decided, based on the knowledge of NPY and leptin effects just summarized, to investigate the role of glucocorticoids in three speci®c situations: (1) on the obesity syndrome produced by chronic intracerebroventricular (i.c.v.) NPY infusion; (2) on the effects of i.c.v. leptin administration to normal rats; (3) on body weight homeostasis of normal rats chronically i.c.v. infused with glucocorticoids.
Results and discussion
Impact of glucocorticoids on the effects of NPY 13 In this study four groups of rats were investigated, normal (sham operated) rats i.c.v. infused with vehicle, normal rats i.c.v. infused with NPY, adrenalectomized rats i.c.v. infused with vehicle, adrenalectomized rats i.c.v. infused with NPY. Infusions were carried out over ®ve days during which food was provided ad libitum. Food intake and body weight were measured daily, and blood sampling was carried out each day for subsequent measurements of hormones and substrates. At the end of the 5-day experimental period, euglycemic ± hyperinsulinemic clamps associated with the labeled 2-deoxy-glucose technique were carried out to measured insulin-stimulated glucose utilization by white adipose tissue and various muscle types. Adipose tissue was also used for measuring the expression of obese (ob) gene. Chronic i.c.v. infusion of NPY resulted, relative to controls, in marked augmentation in food intake and body weight gain, in rapidly occurring and sustained increases in insulinemia, corticosteronemia, and triglyceridemia. After the 5-day experimental period NPY-infusion also produced an increase in the insulin responsiveness of the glucose utilization index of white adipose tissue (with resulting increased adipose tissue weight), but a decrease in that of the glucose utilization process in all muscle types studied (insulin resistance). Finally chronic NPY infusion increased the ob expression of adipose tissue, presumably in plasma leptin levels as well. 13 The striking observation was that, when NPY was similarly infused in adrenalectomized rats, none of the changes summarized above occurred, indicating that, when adrenalectomy had been carried out in obese rodents to reverse their syndrome, the site of this effect was likely to be at or related to NPY-ergic pathways. 13 This viewpoint has been recently strengthened by the observation that, when NPY was i.c.v. infused in adrenalectomized animals together with i.c.v. glucocorticoid, the obesity-like effects of the neuropeptide were present again (manuscript in preparation). Thus, central glucocorticoid are necessary for the i.c.v. NPY-induced effects to occur, demonstrating the relevance of these hormones in body weight homeostasis andaor evolution toward obesity. 13 Impact of glucocorticoids on the effects of leptin 14 In these studies it was hypothesized that leptin, with its action on food intake and body weight largely opposite to those of NPY, could also be under the in¯uence of glucocorticoids. It was therefore decided to compare the effect of an i.c.v. leptin bolus injection on body weight and food intake in normal and adrenalectomized rats. Compared with vehicleinjected control rats, an i.c.v. bolus of leptin (3 mg) given to intact rats produced only moderate and transient decreases in body weight. The situation was quite different when the same dose of leptin was administered to adrenalectomized rats. Indeed, compared to controls infused with the vehicle, i.c.v. leptin, used at the same dose as before, elicited a profound weight loss (about 30 g at nadir) which lasted during the whole experimental (5 days) period. 14 Similar data were obtained when measuring food intake. In addition, glucocorticoid administration to adrenalectomized rats dose-dependently reduced these potent effects of leptin. Thus, leptin effects on food intake and body weight are maximal in the absence of the hormones. Glucocorticoids thus appear to be an important modulator of body weight homeostasis as they limit leptin-induced effects.
14 Impact of glucocorticoids per se on body weight homeostasis 15 Stress' circulating levels of glucocorticoids have been thought for long to play a role in the development of obesity syndromes, including humans with abdominal type of obesity. 16 ± 22 Due to this and to the data summarized above, it was hypothesized that the i.c.v. administration of glucocorticoids (dexamethasone) could possibly, in itself, change body weight homeostasis. Normal rats were therefore i.c.v. infused with vehicle or dexamethasone for three days while measuring food intake, body weight changes, peripheral hormones and substrates. At the end of the experiment, brains were removed for subsequent measurements of hypothalamic CRH and NPY levels. 15 Continuous i.c.v. glucocorticoid infusion resulted in marked, sustained increases in food intake and body weight relative to saline-infused controls. This infusion abolished the endogenous corticosterone output. It produced hyperinsulinemia, hyperleptinemia and hyperlipidemia, three salient abnormalities of obesity syndromes. I.c.v. glucocorticoid infusion markedly decreased the expression of uncoupling proteins 1 and 3. Finally, it increased the hypothalamic levels of NPY, while decreasing those of CRH compared to control animals. 15 The latter changes are the likely cause of the observed increase in food intake, body weight gain, and hormonal levels measured in the i.c.v. glucocorticoid-infused rats, all the more that the intraperitoneal infusion of the same dose of steroid failed to elicit the same changes in hypothalamic neuropeptide levels. 15 
Conclusions
To place the above considerations into some perspective, one should refer to Figure 1 which is an oversimpli®cation of the considerations above. It is proposed that glucocorticoids may have relevant impact on body weight homeostasis and may, under certain conditions, favor the evolution toward obesity, with insulin and leptin resistance. It potentially indicates that changes in the environment may possibly suf®ce to favor the occurrence of obesity syndromes. The molecular mechanisms of such glucocorticoid regulation of body weight homeostasis have yet to be elucidated. 
